DiaMedica Therapeutics (DMAC) Receivables (2017 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Receivables came in at $586000.0 in Q1 2026, up 21.58% year-on-year from $482000.0 in Q1 2025, and up 15.35% quarter-over-quarter from $508000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Receivables (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics' Receivables history runs 10 years deep, the most recent figure standing at $586000.0 for Q1 2026.
- On a quarterly basis, Receivables rose 21.58% year-over-year to $586000.0 in Q1 2026; TTM through Mar 2026 was $586000.0, a 21.58% increase from a year earlier, with the FY2025 full-year figure at $508000.0, up 114.35% from the prior year.
- Receivables advanced to $586000.0 in Q1 2026 per DMAC's latest filing, from $508000.0 in the prior quarter.
- Across five years, Receivables topped out at $790000.0 in Q1 2024 and bottomed at $75000.0 in Q3 2022.
- The 5-year median for Receivables is $440000.0 (2023), against an average of $394823.5.
- Across the five-year window, Receivables plunged 72.84% in 2022 and surged 725.33% in 2023, its largest moves.
- Year by year, Receivables stood at $84000.0 in 2022, then soared by 423.81% to $440000.0 in 2023, then slumped by 46.14% to $237000.0 in 2024, then jumped by 114.35% to $508000.0 in 2025, then gained by 15.35% to $586000.0 in 2026.
- Per Business Quant, the three latest DMAC Receivables figures stand at $586000.0 (Q1 2026), $508000.0 (Q4 2025), and $488000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 4.97 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 938.02 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | DiaMedica Therapeutics | 364.72 Mn | 364.72 Mn | - | 586,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 586,000.00 |
| Dec 31, 2025 | 508,000.00 |
| Sep 30, 2025 | 488,000.00 |
| Jun 30, 2025 | 303,000.00 |
| Mar 31, 2025 | 482,000.00 |
| Dec 31, 2024 | 237,000.00 |
| Sep 30, 2024 | 578,000.00 |
| Jun 30, 2024 | 778,000.00 |
| Mar 31, 2024 | 790,000.00 |
| Dec 31, 2023 | 440,000.00 |
| Sep 30, 2023 | 619,000.00 |
| Jun 30, 2023 | 374,000.00 |
| Mar 31, 2023 | 112,000.00 |
| Dec 31, 2022 | 84,000.00 |
| Sep 30, 2022 | 75,000.00 |
| Jun 30, 2022 | 88,000.00 |
| Mar 31, 2022 | 170,000.00 |
| Dec 31, 2021 | 130,000.00 |
| Sep 30, 2021 | 206,000.00 |
| Jun 30, 2021 | 32,000.00 |